GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hamlet BioPharma AB publ (XSAT:HAMLET B) » Definitions » EV-to-EBITDA

Hamlet BioPharma AB publ (XSAT:HAMLET B) EV-to-EBITDA : -17.70 (As of Jun. 04, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Hamlet BioPharma AB publ EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Hamlet BioPharma AB publ's enterprise value is kr684.49 Mil. Hamlet BioPharma AB publ's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was kr-38.67 Mil. Therefore, Hamlet BioPharma AB publ's EV-to-EBITDA for today is -17.70.

The historical rank and industry rank for Hamlet BioPharma AB publ's EV-to-EBITDA or its related term are showing as below:

XSAT:HAMLET B' s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.7   Med: 0   Max: 0
Current: -17.7

XSAT:HAMLET B's EV-to-EBITDA is ranked worse than
100% of 482 companies
in the Biotechnology industry
Industry Median: 8.795 vs XSAT:HAMLET B: -17.70

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-04), Hamlet BioPharma AB publ's stock price is kr3.965. Hamlet BioPharma AB publ's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was kr-0.281. Therefore, Hamlet BioPharma AB publ's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Hamlet BioPharma AB publ EV-to-EBITDA Historical Data

The historical data trend for Hamlet BioPharma AB publ's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hamlet BioPharma AB publ EV-to-EBITDA Chart

Hamlet BioPharma AB publ Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.98 -110.05 -22.88 -14.74 -20.39

Hamlet BioPharma AB publ Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.61 -20.39 -20.16 -16.40 -17.72

Competitive Comparison of Hamlet BioPharma AB publ's EV-to-EBITDA

For the Biotechnology subindustry, Hamlet BioPharma AB publ's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hamlet BioPharma AB publ's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hamlet BioPharma AB publ's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Hamlet BioPharma AB publ's EV-to-EBITDA falls into.


;
;

Hamlet BioPharma AB publ EV-to-EBITDA Calculation

Hamlet BioPharma AB publ's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=684.494/-38.672
=-17.70

Hamlet BioPharma AB publ's current Enterprise Value is kr684.49 Mil.
Hamlet BioPharma AB publ's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-38.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hamlet BioPharma AB publ  (XSAT:HAMLET B) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Hamlet BioPharma AB publ's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3.965/-0.281
=At Loss

Hamlet BioPharma AB publ's share price for today is kr3.965.
Hamlet BioPharma AB publ's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.281.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Hamlet BioPharma AB publ EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Hamlet BioPharma AB publ's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Hamlet BioPharma AB publ Business Description

Traded in Other Exchanges
N/A
Address
Klinikgatan 32, BMC D10, Lund, SWE, SE-222 42
Hamlet BioPharma AB publ is a pharmaceutical company engaged in the research and development of drugs used for curing cancer.

Hamlet BioPharma AB publ Headlines

No Headlines